Supplementary Figure 1 from Exploration of Immune-Modulatory Effects of Amivantamab in Combination with Pembrolizumab in Lung and Head and Neck Squamous Cell Carcinoma | Synapse
July 17, 2024
Supplementary Figure 1 from Exploration of Immune-Modulatory Effects of Amivantamab in Combination with Pembrolizumab in Lung and Head and Neck Squamous Cell Carcinoma
Puntos clave
Los puntos clave no están disponibles para este artículo en este momento.
Resumen
This figure entails the selection of HNSCC and LUSC PDX model based on the H-score of EGFR and MET.